Search results (68)
« Back to PublicationsAge differences in immunity to human seasonal coronaviruses and the immunogenicity of ChAdOx1 nCoV-19 (AZD1222).
Journal article
Belij-Rammerstorfer S. et al, (2025), EBioMedicine, 118
Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in Brazil.
Journal article
Costa Clemens SA. et al, (2025), Mayo Clin Proc Innov Qual Outcomes, 9
Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials.
Journal article
Venkatraman N. et al, (2025), Lancet Microbe, 6
Rift Valley fever seroprevalence and risk factors among human populations in Uganda's cattle corridor: a cross-sectional study.
Journal article
Anywaine Z. et al, (2025), BMJ Public Health, 3
Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trial.
Journal article
Satti I. et al, (2024), Lancet Infect Dis, 24, 909 - 921
Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Ebola, Sudan, Marburg and Lassa viruse.
Journal article
Flaxman A. et al, (2024), PLoS Pathog, 20
Low-dose M.tb infection but not BCG or MTBVAC vaccination enhances heterologous antibody titres in non-human primates.
Journal article
Peralta Alvarez MP. et al, (2024), Front Immunol, 15
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial.
Journal article
Hamaluba M. et al, (2023), Wellcome open research, 8, 182 - 182
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial
Journal article
Hamaluba M. et al, (2023), Wellcome Open Research, 8, 182 - 182
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial
Journal article
Hamaluba M. et al, (2023), Wellcome Open Research, 8
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial
Journal article
Hamaluba M. et al, (2023), Wellcome Open Research, 8, 182 - 182
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial
Journal article
Hamaluba M. et al, (2023), Wellcome Open Research, 8, 182 - 182
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial
Journal article
Hamaluba M. et al, (2023), Wellcome Open Research, 8
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial.
Journal article
Hamaluba M. et al, (2023), Wellcome Open Res, 8